Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.

It’s time for a new era of public health—where vaccines are seen as both a scientific triumph and a shared commitment to well ...

In addition, TransCelerate executives and member organizations, such as Amgen, Eli Lilly, GSK, and more, will present 10 impactful sessions at the conference, addressing critical and relevant topics ...

The UK biotech sector raised £3.5 billion in equity financing last year amid challenges, according to a BIA report.

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top ...

Speculation is mounting GlaxoSmithKline's CEO Emma Walmsley may pay the price for the company’s lacklustre performance, after the dreaded activist investor Elliott Management built a stake in ...

GlaxoSmithKline (GSK) appears to be focusing more on finding a new CEO than any large M&A deals after last year's $20 billion asset swap with Novartis, according to a briefing following strong Q1 ...

The Marketing Association of Pakistan (MAP) has announced its newly elected office bearers and Council members. Muhammad ...

Appasamy Associates has appointed Annaswamy Vaidheesh as its non-executive chairman. With over 35 years of experience in the ...

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. | Takeda has named Julie Kim ...